|Bid||35.80 x 1400|
|Ask||36.49 x 1300|
|Day's Range||34.21 - 35.94|
|52 Week Range||25.04 - 43.16|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Benzinga's PreMarket Prep show resumed Thursday after a pause for the Christmas holiday. As always, there were a few market movers to cover and two informative interviews. Qiagen Decides Not To Sell When ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...
Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business. Qiagen announced last month that it had received "several" entreaties to acquire the molecular-diagnostics specialist, and were exploring the opportunities. Shares, which had been hit hard by a CEO departure and China-related concerns, rebounded on that news. After the shortened Christmas Eve trading session ended, though, Qiagen announced that its management and supervisory boards had opted against a sale and terminated all discussions because "the alternatives to the stand-alone business plan prospects were not compelling." Shares closed Tuesday with a 0.8% increase at $41.47, then dove to less than $31 in after-hours trading following the announcement.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
QIAGEN and DiaSorin receive FDA approval for the LIAISON QuantiFERON-TB Gold Plus Test on LIAISON platforms and begin commercial launch
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
Shares of Dutch genetic testing company Qiagen shot higher on Monday, after the company confirmed it had entered into discussions to “explore potential strategic alternatives” after receiving ”several nonbinding indications of interest.”
Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors. The shares had gained 14% on Wednesday, after a report that life sciences tools maker Thermo Fisher Scientific Inc had approached Qiagen about a potential deal. "The Supervisory Board and the Management Board ... are starting discussions with interested parties," the company said on Friday.
European stocks on Monday held on to levels they reached after six straight winning weeks, with most of the movement occurring in merger situations.
European shares edged closer to a record level on Monday, as optimism around U.S.-China trade talks and a surprise move by China's central bank in cutting a key interest rate painted an upbeat picture about global growth. The pan-European STOXX 600 index rose 0.17% by 0814 GMT, extending gains after its six-week winning streak. Also adding to the positive sentiment was news that China's central bank unexpectedly trimmed a closely watched lending rate for the first time in more than four years on Monday, a signal that policymakers are ready to act to prop up slowing growth.
Dutch genetic-testing company Qiagen confirmed late Friday it's fielding several offers from potential suitors interested in acquiring it. Qiagen stock rose 8.8% on Friday.
Qiagen NV said on Friday it has started reviewing options, including sale, after the genetic testing company received several indications of interest for acquisition, sending its U.S. listed shares up 8.5%. The company, which has a market capitalization of $8.6 billion as of Thursday's close, said its management will start talks with interested parties as part of the review. Instruments maker Thermo Fisher Scientific Inc approached Qiagen about a potential deal, Bloomberg reported on Wednesday.
Qiagen stock popped in bullish volume Thursday on a report medical technology giant Thermo Fisher Scientific could buy it for $8 billion. It would be one of Thermo Fisher's biggest buys.
The swing to a bullish rating for Qiagen follows “our recent buy-side survey, two new product surveys, and valuation analysis,” Peterson said in the upgrade note. Barring this, there seems to be potential for the company’s new management team to reset the bar and capitalize on portfolio rationalization and cost reduction opportunities, Peterson mentioned.
Shares of Qiagen N.V. surged 3.3% in premarket trading Thursday, after J.P. Morgan analyst Tycho Peterson swung to bullish from bearish on the Netherlands-based molecular testing company, citing expectations that company's turnaround will continue. The upgrade comes a day after the stock surged 9.9% after a Bloomberg report that Massachusetts-based analysis and diagnostics company Thermo Fisher Scientific Inc. was considering a buyout of Qiagen, which had a market capitalization of $8.03 billion as of Wednesday's close. J.P. Morgan's Peterson upgraded Qiagen to overweight from underweight and boosted his price target to $40 from $25. "Barring a near-term takeout..., we see potential for new management to reset the bar and pursue abundant opportunities for portfolio rationalization and cost reduction, and therefore we think the worst is in the rearview for [Qiagen]," Peterson wrote in a note to clients. The stock has run up 40% since closing at a 3-year low on Oct. 8 through Wednesday, while the S&P 500 has gained 6.9% over the same time.